August 2022 tender notification
Pharmac is pleased to provide the latest tender results.
Download the tender notification [PDF 67 KB]
Tender results
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender (ITT) dated 2 November 2020, and the 2021/22 Invitation to Tender, dated 1 November 2021.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 September 2022 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2020/21 Tender – Principal Supply Status applies until 30 June 2024
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
Date of listing |
Principal Supply Status date |
Brand |
|---|---|---|---|---|---|---|---|
|
Midodrine1 |
Tab 2.5 mg; 100 tablet blister pack |
$53.00 |
$38.23 |
Midodrine Medsurge (Medsurge) |
1 March 2023 |
1 August 2023 |
Gutron (Douglas) |
|
Midodrine1 |
Tab 5 mg; 100 tablet blister pack |
$79.00 |
$59.98 |
Midodrine Medsurge (Medsurge) |
1 March 2023 |
1 August 2023 |
Gutron (Douglas) |
|
1Brand Switch Fee of $4.50 is payable for this product from 1 August 2023 to 31 October 2023. |
|||||||
Hospital pharmaceutical tenders – Part II of Section H of the Pharmaceutical Schedule
2. Tenders awarded to currently listed pharmaceuticals where no brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
New |
Principal Supply brand (Supplier) |
DV limit |
Date of listing |
Principal Supply Status date |
|---|---|---|---|---|---|---|
|
Midodrine |
Tab 2.5 mg; 100 tablet blister pack |
$38.23 |
Midodrine Medsurge (Medsurge) |
5% |
1 March 2023 |
1 August 2023 |
|
Midodrine |
Tab 5 mg; 100 tablet blister pack |
$59.98 |
Midodrine Medsurge (Medsurge) |
5% |
1 March 2023 |
1 August 2023 |
2021/22 Tender – Principal Supply Status applies until 30 June 2025
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
3. Tenders awarded to Pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
Date of listing |
Principal Supply Status date |
Brand |
|---|---|---|---|---|---|---|---|
|
Ethinyloestradiol with levonorgestrel |
Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets; 84 tablet blister pack2 |
$2.18 (per 84) $6.45 (per 112) |
$1.50 |
Lo-Oralcon 20 ED (Viatris) |
1 March 2023 |
1 August 2023 |
Microgynon 20 ED (Bayer) Femme-Tab ED (AFT) |
|
Ethinyloestradiol with levonorgestrel |
Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets; 84 tablet blister pack2 |
$1.77 (per 84) $6.45 (per 112) |
$1.50 |
Oralcon 30 ED (Viatris) |
1 March 2023 |
1 August 2023 |
Levlen ED (Bayer) Femme-Tab ED (AFT) |
|
Ondansetron |
Tab 4 mg; 50 tablet blister pack |
$2.68 |
$2.27 |
Periset (Miro) |
1 March 2023 |
1 August 2023 |
Onrex (Rex Medical) |
|
Ondansetron |
Tab 8 mg; 50 tablet blister pack |
$4.57 |
$4.10 |
Periset (Miro) |
1 March 2023 |
1 August 2023 |
Onrex (Rex Medical) |
|
Posaconazole |
Oral liq 40 mg per ml; 105 ml bottle OP |
$761.13 |
$342.51 |
Devatis (Devatis) |
1 December 2022 |
1 May 2023 |
Noxafil (MSD) |
|
2The PSO quantity for this product will be amended from 112 to 84 tablets from 1 August 2023 |
|||||||
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
4. Tenders awarded to Pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand (Supplier) |
DV Limit |
Listing date |
Principal Supply Status date |
Brand |
|---|---|---|---|---|---|---|---|---|
|
Ethinyloestradiol with levonorgestrel |
Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets; 84 tablet blister pack |
$2.18 |
$1.50 |
Lo-Oralcon 20 ED (Viatris) |
5% |
1 March 2023 |
1 August 2023 |
Microgynon 20 ED (Bayer) |
|
Ethinyloestradiol with levonorgestrel |
Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets; 84 tablet blister pack |
$1.77 |
$1.50 |
Oralcon 30 ED (Viatris) |
5% |
1 March 2023 |
1 August 2023 |
Levlen ED (Bayer) |
|
Ondansetron |
Tab 4 mg; 50 tablet blister pack |
$2.68 |
$2.27 |
Periset (Miro) |
5% |
1 March 2023 |
1 August 2023 |
Onrex (Rex Medical) |
|
Ondansetron |
Tab 8 mg; 50 tablet blister pack |
$4.57 |
$4.10 |
Periset (Miro) |
5% |
1 March 2023 |
1 August 2023 |
Onrex (Rex Medical) |
|
Posaconazole |
Oral liq 40 mg per ml; 105 ml bottle |
$761.13 |
$342.51 |
Devatis (Devatis) |
5% |
1 December 2022 |
1 May 2023 |
Noxafil (MSD) |
|
Voriconazole |
Inj 200 mg vial; 1 vial pack |
$44.00 |
$19.85 |
AFT (AFT) |
5% |
1 March 2023 |
1 August 2023 |
Neo Health (Neo Health) |
Tender declines - Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2021/22 Invitation to Tender, dated 1 November 2021
2021/22 Invitation to Tender
|
Chemical name |
Line item |
|
Risperidone |
Inj 25 mg |
|
Risperidone |
Inj 37.5 mg |
|
Risperidone |
Inj 50 mg |
For products included in the 2019/20, 2020/21 or 2021/22 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.